Literature DB >> 3625479

Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum.

R W Wittendorf, J E Swagzdis, R Gifford, B A Mico.   

Abstract

In previous studies of the pharmacokinetics and urinary excretion of nine glycopeptides with diverse isoelectric points (pI), as pI decreases, the total systemic and renal clearance, urinary recovery, and volume of distribution decrease, whereas the half-life increases. With glycopeptides of similar pI, clearance decreases and half-life increases with increasing lipophilicity. The present study examines the serum protein binding of these glycopeptide antibiotics in mouse, rat, and human serum and calculates the previously reported pharmacokinetic parameters for these drugs based on unbound concentration. Increased negative charge and lipophilicity increase serum protein binding (90-fold, fu 83% to 0.96%), which decreases the renal clearance and total systemic clearance (90-fold, 16.4 to 0.18 ml/min/kg) of these drugs. Increased serum protein binding also decreases the volume of distribution of these compounds, but this change is relatively small (sixfold, 755 to 131 ml/kg) compared with the change in total systemic clearance causing an increase in elimination half-life (25-fold, 20 to 492 min). The results demonstrate that the large differences in the total systemic clearance and half-life of these glycopeptide antibiotics are primarily due to dramatic differences in serum protein binding and not to differences in the intrinsic elimination processes (enzymes or transport proteins). It appears that the same physical-chemical properties that govern the protein binding and pharmacokinetics of small organic molecules govern the disposition of these high-molecular weight glycopeptide antibiotics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3625479     DOI: 10.1007/BF01062935

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

Review 1.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 2.  Plasma and tissue protein binding of drugs in pharmacokinetics.

Authors:  W J Jusko; M Gretch
Journal:  Drug Metab Rev       Date:  1976       Impact factor: 4.518

3.  Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.

Authors:  J K Seydel; D Trettin; H P Cordes; O Wassermann; M Malyusz
Journal:  J Med Chem       Date:  1980-06       Impact factor: 7.446

4.  Effect of altered plasma protein binding on apparent volume of distribution.

Authors:  S Oie; T N Tozer
Journal:  J Pharm Sci       Date:  1979-09       Impact factor: 3.534

5.  Aridicins, novel glycopeptide antibiotics. I. Taxonomy, production and biological activity.

Authors:  M C Shearer; P Actor; B A Bowie; S F Grappel; C H Nash; D J Newman; Y K Oh; C H Pan; L J Nisbet
Journal:  J Antibiot (Tokyo)       Date:  1985-05       Impact factor: 2.649

6.  Aridicins, novel glycopeptide antibiotics. II. Isolation and characterization.

Authors:  R D Sitrin; G W Chan; J J Dingerdissen; W Holl; J R Hoover; J R Valenta; L Webb; K M Snader
Journal:  J Antibiot (Tokyo)       Date:  1985-05       Impact factor: 2.649

7.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Authors:  P H Hinderling; O Schmidlin; J K Seydel
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

8.  Structure-pharmacokinetic relationships among the barbiturates in the rat.

Authors:  S Toon; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

9.  Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis.

Authors:  F D Boudinot; W J Jusko
Journal:  J Pharm Sci       Date:  1984-06       Impact factor: 3.534

10.  Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.

Authors:  D H Pitkin; B A Mico; R D Sitrin; L J Nisbet
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

  10 in total
  7 in total

1.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.

Authors:  Christian Radke; Dagmar Horn; Christian Lanckohr; Björn Ellger; Michaela Meyer; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

3.  Pharmacokinetics of individual components of teicoplanin in man.

Authors:  A Bernareggi; A Danese; A Cometti; G Buniva; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

4.  Serum protein-binding characteristics of vancomycin.

Authors:  H Sun; E G Maderazo; A R Krusell
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 6.  Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences.

Authors:  Hifza Ahmed; Felix Bergmann; Markus Zeitlinger
Journal:  Antibiotics (Basel)       Date:  2022-07-08

7.  Uncoupling of invasive bacterial mucosal immunogenicity from pathogenicity.

Authors:  Simona P Pfister; Olivier P Schären; Luca Beldi; Andrea Printz; Matheus D Notter; Mohana Mukherjee; Hai Li; Julien P Limenitakis; Joel P Werren; Disha Tandon; Miguelangel Cuenca; Stefanie Hagemann; Stephanie S Uster; Miguel A Terrazos; Mercedes Gomez de Agüero; Christian M Schürch; Fernanda M Coelho; Roy Curtiss; Emma Slack; Maria L Balmer; Siegfried Hapfelmeier
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.